Lung Cancer Clinical Trial
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
Summary
The purposes of this study are to determine the following:
Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long.
If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer.
The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs.
How LY900003 is distributed and broken down by your body when it is given with carboplatin and gemcitabine.
Whether LY900003 affects the way gemcitabine and carboplatin are distributed and broken down by your body.
Full Description
Definition: The phase 2 study will provide important information regarding effects of LY900003 on safety and efficacy of patients treated with gemcitabine and carboplatin. LY900003 will be given at approximately 2 mg/kg/day for the first 14 days of a 21-day cycle. The dose and schedule for LY900003 administration are based on results of prior studies of LY900003 and are currently being used in other studies of LY900003. Gemcitabine will be administered on Days 1 and 8 at 1250 mg/m2 and carboplatin will be given on Day 1 at AUC 5.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of Non-Small-Cell Lung Cancer.
Stage IV or Stage IIIB disease.
ECOG Performance Status of 0 or 1.
Adequate organ function
One unidimensionally measurable lesion.
Exclusion Criteria:
Prior therapy for NSCLC.
Serious concomitant disorders.
Untreated CNS metastases.
Uncontrolled, active infection.
Previous LY900003/ISIS trial participation.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Bakersfield California, , United States
Berkeley California, , United States
Torrance California, , United States
Miami Beach Florida, , United States
Chicago Illinois, , United States
Park Ridge Illinois, , United States
Baltimore Maryland, , United States
Chattanooga Tennessee, , United States
Lubbock Texas, , United States
Charlottesville Virginia, , United States
Milwaukee Wisconsin, , United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.